A pilot study to evaluate the safety of intravenously administered human amnion epithelial cells in patients with compensated cirrhosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1124020

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We propose a first-in-man clinical trial of human amnion epithelial cells (hAEC), a stem cell from the placenta, to assess safety in patients with stable liver cirrhosis. Worldwide, cirrhosis is the 6th most common cause of death. Liver transplantation remains the only chance for survival for some people with cirrhosis. In animal models, hAEC can substantially reduce liver scar tissue. Our goal is to develop hAEC as a therapy to reduce the need for liver transplantation.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $394,692.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Gastroenterology and Hepatology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cell therapy | cirrhosis | clinical trial | hepatic fibrosis | stem cells

Related Links